Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Salvage therapy at biochemical recurrence of prostate cancer

Nature Reviews Urology volume 17, pages 195–196 (2020)Cite this article

Subjects

No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques, prostate-specific antigen (PSA) levels at time of salvage radiotherapy (SRT), use of SRT ± salvage androgen deprivation therapy based on PSA levels, and the interval to biochemical failure.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Post-prostatectomy failure patterns and their optimal treatments.

References

  1. Yokomizo, A. et al. Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401). Eur. Urol. https://doi.org/10.1016/j.eururo.2019.11.023 (2019).

    Article  PubMed  Google Scholar 

  2. Zaorsky, N. G. et al. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol. 10, 457–474 (2014).

    Article  CAS  Google Scholar 

  3. Calais, J. et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286–1294 (2019).

    Article  CAS  Google Scholar 

  4. Panebianco, V. et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur. Radiol. 23, 1745–1752 (2013).

    Article  Google Scholar 

  5. Tendulkar, R. D. et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J. Clin. Oncol. 34, 3648–3654 (2016).

    Article  Google Scholar 

  6. Stish, B. J. et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J. Clin. Oncol. 34, 3864–3871 (2016).

    Article  Google Scholar 

  7. Carrie, C. et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 20, 1740–1749 (2019).

    Article  CAS  Google Scholar 

  8. Shipley, W. U. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med. 376, 417–428 (2017).

    Article  Google Scholar 

  9. Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727–737 (2016).

    Article  CAS  Google Scholar 

  10. Pollack, A. et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiation therapy: the NRG Oncology/RTOG 0534 SPPORT Trial. Int. J. Radiat. Oncol. Biol. Phys. 102, 1605 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA

    Nicholas G. Zaorsky

  2. Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA

    Nicholas G. Zaorsky

  3. Department of Radiation Oncology, UCLA, Los Angeles, CA, USA

    Amar U. Kishan

Authors
  1. Nicholas G. Zaorsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amar U. Kishan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas G. Zaorsky.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

AUA guidelines: https://www.auanet.org/guidelines/prostate-cancer-adjuvant-and-salvage-radiotherapy-guideline

EAU guidelines: https://uroweb.org/guideline/prostate-cancer/

NCCN guidelines: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaorsky, N.G., Kishan, A.U. Salvage therapy at biochemical recurrence of prostate cancer. Nat Rev Urol 17, 195–196 (2020). https://doi.org/10.1038/s41585-020-0290-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-020-0290-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing